The trial’s sponsor announced an early end to the large Alzheimer’s prevention study based on an interim futility analysis.
The more risk variants in a person’s genome, the faster they decline on both cognitive and motor tests.
Antibody comes close, but can’t slow mild AD.
In ADNI, only a handful of variants associate with amyloid PET. Their impact may vary by disease stage.
Three new studies agree that cellular stress favors noncanonical translation of dipeptide repeats from an intron in the C9ORF72 gene, but diverge on the exact mechanism.
Scientists elucidate a new pathway by which salt triggers adaptive immune cell responses in the gut, which harm memory without driving up blood pressure.
A pilot study finds that depriving people of sleep bumps up their nightly Aβ production.
The shed domain of this microglia receptor sticks to plaques and neurons. Not so for the R47H AD variant, however.
Using whole-genome sequence analysis, researchers find genetic variants linked to white-matter integrity, and cerebral and hippocampal volume.
A new protein-labeling technique puts TDP-43 on the growing list of neurodegeneration-associated proteins that displace nucleoporins and nuclear transport factors.
Though memory scores were more likely to slide in cognitively normal people who tested positive for brain amyloid deposition, this decline alone was unable to predict early Alzheimer’s disease.
Multiple variants in and around the LRRK2 gene raise or lower risk for both diseases together, hinting at similar underlying mechanisms.
Initial report touted positive exploratory results for nelotanserin, but a correction wiped out optimism.
Publication of negative results of Phase 3 idalopirdine trials lays to rest yet another candidate drug.
An anti-Aβ antibody holding a transferrin ticket to the brain stokes an immune response against Aβ, but not against the transport system.